Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.
about
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaThe β-Lactams Strike Back: Ceftazidime-AvibactamCeftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsNew β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.Investigational antimicrobial agents of 2013.Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model.Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa.Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjectsIn Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-AvibactamSingle- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjectsIn vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.Will new antimicrobials overcome resistance among Gram-negatives?Ceftazidime for respiratory infections.Combating multidrug-resistant Gram-negative bacterial infections.Cephalosporins currently in early clinical trials for the treatment of bacterial infections.Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model.Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment.Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa.Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic modelIn vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assaysEnantioselective Synthesis and Profiling of Two Novel Diazabicyclooctanone β-Lactamase InhibitorsComparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 β-Lactamase.
P2860
Q24601746-42920E7E-6D6C-42DD-AA57-3967268A06EEQ26796425-C3FB9BDE-2951-442D-A6FC-AC5A4857E74CQ28069563-4780B098-BED6-47EB-BCC0-75E786CBB7CCQ33622976-6071A106-9713-487D-8636-3A94D7DFFF3FQ34058217-FAD4DA7B-3A82-4A3D-A82E-F7CE0B97A68AQ34325573-32D7D0F6-E497-4CEC-908D-96F837E5DA40Q34375204-6A72839A-4A8F-4D4C-9375-5F786D83429CQ34402134-ABE41643-75E4-4585-93E9-18ECF385F627Q34596516-826835E0-EB1F-4B1F-A04E-4B8EA1FF5B30Q34596918-4D704C1D-C210-49C3-A407-2C2997972ACDQ35105960-9DAFAE2C-7EE0-49A6-8A26-8775C18115BCQ35168955-2B93DEE4-AE24-451C-90A9-1F840C433D1AQ36201543-3EC65C8D-9A6E-4192-BD59-3CD3CA668D8CQ36290482-2B5B19BF-28B8-4B4D-853D-FEA7028BB9D5Q36439179-B0D5AAB7-3F90-4182-B07E-4302DBA3D531Q36644679-1BD0E3FD-241E-4EA8-8B1D-0F12DEF25B3BQ36667104-03572F3E-26C4-428E-90A2-884DD8E1F40CQ37643595-014691A2-2F44-4210-84FD-83B3499EFE08Q37942654-0BAA7BE6-6CD3-423C-A96E-435705E5082BQ38040144-C0396A2F-D1DC-4AF5-826A-6FE1BD76B1FBQ38161570-0104B1FA-154B-4DD7-B17B-723D81DE8F82Q38222497-1CE2EA8D-FA97-4D9C-8683-51F1E0B9010EQ38367722-FBF2B5F9-9E53-45C7-B2B4-1B25CB9AA3A4Q38543002-7081F739-27FA-4AD7-B4A2-AF1C5B72969EQ38595451-335D0AEA-C5B2-4F7A-8345-F288219454C6Q38797485-856823CD-FE41-4F40-B636-8CA0085E2C44Q40248058-5BBE7E3D-2C22-426C-8F88-933FE45609FBQ40617686-C5F65B52-9386-4819-A346-645E40CDFF9AQ40617746-92F9A797-34E9-462E-AFAC-0CC85A0E0B0BQ40676639-8266E9B1-1AD3-472A-BBE3-266419F62178Q40967518-5C6F792B-F648-4DF4-B68F-0C03192B0F26Q41077573-8896B3CE-9B2D-4776-92E4-AB5D03AFEF1FQ41240109-0F62053C-4839-496F-A062-25EFD32C31BEQ41379541-949F6BFF-420D-4B72-9173-400C9CD4BAAEQ41547467-2CDB169A-E947-4F0E-89DB-53B6DC2760BAQ41610058-E85352FD-8EC7-474B-BE38-8E7D0EB9F373Q41702200-9DFA626B-A3C0-47A1-BAFD-3C04FF3612ACQ42275878-906D8132-E02D-4679-826F-33EE888C2084Q43045719-7ED108C0-84C0-4508-8640-A79F0AB3F435Q45199846-313C712C-BF39-46B1-B473-9D1311A6A5EF
P2860
Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Activity of NXL104 in combinat ...... s and class C beta-lactamases.
@ast
Activity of NXL104 in combinat ...... s and class C beta-lactamases.
@en
Activity of NXL104 in combinat ...... s and class C beta-lactamases.
@nl
type
label
Activity of NXL104 in combinat ...... s and class C beta-lactamases.
@ast
Activity of NXL104 in combinat ...... s and class C beta-lactamases.
@en
Activity of NXL104 in combinat ...... s and class C beta-lactamases.
@nl
prefLabel
Activity of NXL104 in combinat ...... s and class C beta-lactamases.
@ast
Activity of NXL104 in combinat ...... s and class C beta-lactamases.
@en
Activity of NXL104 in combinat ...... s and class C beta-lactamases.
@nl
P2093
P2860
P356
P1476
Activity of NXL104 in combinat ...... es and class C beta-lactamases
@en
P2093
G G Zhanel
J A Karlowsky
P2860
P304
P356
10.1128/AAC.01722-10
P407
P577
2011-02-28T00:00:00Z